NCT05773729View on ClinicalTrials.gov

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia

NARecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

October 31, 2026

Conditions
β-thalassemia
Interventions
GENETIC

BD211

Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.

Trial Locations (1)

200127

RECRUITING

Shanghai Children's Medical Centre, Shanghai

All Listed Sponsors
collaborator

Shanghai Children's Medical Center

OTHER

lead

Shanghai BDgene Co., Ltd.

INDUSTRY